Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue $ 207 $ 0 $ 325  
Cost of goods sold 62 0 161  
Gross profit 145 0 164  
Research and development 1,667 5,718 2,933 $ 10,645
General and administrative 6,480 16,608 13,751 24,464
Depreciation and amortization 49 22 91 43
Total operating expenses 8,196 22,348 16,775 35,152
Loss from operations (8,051) (22,348) (16,611) (35,152)
Other income (expense):        
Interest income, net   3 1 43
Loss on foreign currency translation   (1)   (1)
Loss before income taxes (8,051) (22,346) (16,610) (35,110)
Income taxes (benefit) 0 0    
Net loss (8,051) (22,346) (16,610) (35,110)
Non-controlling interest 350 3,158 590 4,586
Net loss attributable to BioSig Technologies, Inc. (7,701) (19,188) (16,020) (30,524)
Preferred stock dividend (3) (5) (5) (9)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (7,704) $ (19,193) $ (16,025) $ (30,533)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.24) $ (0.72) $ (0.50) $ (1.20)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 32,169,191 26,537,058 31,878,283 25,463,154
Product [Member]        
Revenue $ 199 $ 0 $ 314  
Service [Member]        
Revenue $ 8 $ 0 $ 11